Extracellular vesicles as modulators of the cancer microenvironment

Seminars in Cell and Developmental Biology

Volumn 40, Issue , 2015, Pages 27-34

  Webber, Jason ^a   Yeung, Vincent ^a   Clayton, Aled ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Exosomes; Immune evasion; Metastatic niche; Microvesicles; Stroma

Indexed keywords

ANGIOGENIC PROTEIN; MESSENGER RNA;

ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CELL ACTIVATION; EXOSOME; FIBROBLAST; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; LYMPHOCYTE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STROMA CELL; METASTASIS; NONHUMAN; REVIEW; STROMA CELL; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR ESCAPE;

ANIMALS; EXTRACELLULAR VESICLES; HUMANS; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84929293007     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.01.013     Document Type: Review

References (95)

1. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006, 66:4795-4801.
2. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics 2010, 9:1085-1099.
3. Clayton A., Turkes A., Navabi H., Mason M.D., Tabi Z. Induction of heat shock proteins in B-cell exosomes. J Cell Sci 2005, 118:3631-3638.
4. de Jong O.G., Verhaar M.C., Chen Y., Vader P., Gremmels H., Posthuma G., et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J Extracell Vesicles 2012, 1:18396.
5. Gould S.J., Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles 2013, 2. 10.3402/jev.v2i0.20389.
6. Pilzer D., Gasser O., Moskovich O., Schifferli J.A., Fishelson Z. Emission of membrane vesicles: roles in complement resistance, immunity and cancer. Springer Semin Immunopathol 2005, 27:375-387.
7. Johnstone R., Adam M., Hammond J., Orr L., Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987, 262:9412-9420.
8. Raposo G., Nijman H.W., Stoorvogel W., Leijendekker R., Harding C.V., Melief C.J.M., et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996, 183:1161-1172.
9. Booth A.M., Fang Y., Fallon J.K., Yang J.-M., Hildreth J.E.K., Gould S.J. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. J Cell Biol 2006, 172:923-935.
10. Webber J., Clayton A. How pure are your vesicles?. J Extracell Vesicles 2013, 19861.
11. Svensson K.J., Christianson H.C., Wittrup A., Bourseau-Guilmain E., Lindqvist E., Svensson L.M., et al. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid raft-mediated endocytosis negatively regulated by caveolin-1. J Biol Chem 2013, 288:17713-17724.
12. del Conde I., Shrimpton C.N., Thiagarajan P., López J.A. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005, 106:1604-1611.
13. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008, 10:619-624.
14. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360:295-305.
15. Lamparski H., Metha-Damani A., Yao J., Patel S., Hsu D., Ruegg C., et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002, 270:211-226.
16. Morse M., Garst J., Osada T., Khan S., Hobeika A., Clay T., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3:9.
17. Escudier B., Dorval T., Chaput N., André F., Caby M., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005, 3:10.
18. Chaput N., Schartz N.E.C., Andre F., Taieb J., Novault S., Bonnaventure P., et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004, 172:2137-2146.
19. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001, 7:297-303.
20. Zeelenberg I.S., Ostrowski M., Krumeich S., Bobrie A., Jancic C., Boissonnas A., et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 2008, 68:1228-1235.
21. Weilin C., Jianli W., Chuansen S., Shuxun L., Yizhi Y., Qingqing W., et al. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 2006, 36:1598-1607.
22. Dai S., Zhou X., Wang B., Wang Q., Fu Y., Chen T., et al. Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8+ CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med 2006, 84:1067-1076.
23. Gehrmann U., Hiltbrunner S., Georgoudaki A.-M., Karlsson M.C., Näslund T.I., Gabrielsson S. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes. Cancer Res 2013, 73:3865-3876.
24. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002, 195:1303-1316.
25. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128:1796-1804.
26. Taylor D.D., Gerçel-Taylor Ç., Lyons K.S., Stanson J., Whiteside T.L. T-cell apoptosis and suppression of T-cell receptor/CD3-ξ by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003, 9:5113-5119.
27. Klibi J., Niki T., Riedel A., Pioche-Durieu C., Souquere S., Rubinstein E., et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113:1957-1966.
28. Taylor D., Gerçel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 2005, 92:305-311.
29. Sutherland C.L., Rabinovich B., Chalupny N.J., Brawand P., Miller R., Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 2006, 108:1313-1319.
30. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
31. Clayton A., Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 2005, 34:206-213.
32. Clayton A., Mitchell J.P., Court J., Linnane S., Mason M.D., Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008, 180:7249-7258.
33. Hedlund M., Stenqvist A.-C., Nagaeva O., Kjellberg L., Wulff M., Baranov V., et al. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol 2009, 183:340-351.
34. Liu C., Yu S., Zinn K., Wang J., Zhang L., Jia Y., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006, 176:1375-1385.
35. Reiners K.S., Topolar D., Henke A., Simhadri V.R., Kessler J., Sauer M., et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood 2013, 121:3658-3665.
36. Clayton A., Mitchell J.P., Court J., Mason M.D., Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007, 67:7458-7466.
37. Szajnik M., Czystowska M., Szczepanski M.J., Mandapathil M., Whiteside T.L. tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS ONE 2010, 5:e11469.
38. Wieckowski E.U., Visus C., Szajnik M., Szczepanski M.J., Storkus W.J., Whiteside T.L. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009, 183:3720-3730.
39. Wada J., Onishi H., Suzuki H., Yamasaki A., Nagai S., Morisaki T., et al. Surface-bound TGF-beta-1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res 2010, 30:3747-3757.
40. Yu L., Yang F., Jiang L., Chen Y., Wang K., Xu F., et al. Exosomes with membrane-associated TGF-β1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur J Immunol 2013, 43:2461-2472.
41. Mokarizadeh A., Delirezh N., Morshedi A., Mosayebi G., Farshid A.-A., Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett 2012, 147:47-54.
42. Yang C., Kim S.-H., Bianco N.R., Robbins P.D. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS ONE 2011, 6:e22517.
43. Valenti R., Huber V., Filipazzi P., Pilla L., Sovena G., Villa A., et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-{beta}-mediated suppressive activity on T lymphocytes. Cancer Res 2006, 66:9290-9298.
44. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007, 178:6867-6875.
45. Xiang A., P C., L Y., L Z.B., D J.W., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009, 124:2621-2633.
46. Liu Y., Xiang X., Zhuang X., Zhang S., Liu C., Cheng Z., et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol 2010, 176:2490-2499.
47. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010, 120:457-471.
48. Battke C., Ruiss R., Welsch U., Wimberger P., Lang S., Jochum S., et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother 2011, 60:639-648.
49. Clayton A., Al-Taei S., Webber J., Mason M.D., Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011, 187:676-683.
50. Cao Y., Arbiser J., D'Amato R.J., D'Amore P.A., Ingber D.E., Kerbel R., et al. Forty-year journey of angiogenesis translational research. Sci Transl Med 2011, 3:114rv3.
51. Welti J., Loges S., Dimmeler S., Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013, 123:3190-3200.
52. Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010, 13:16-28.
53. Gesierich S., Berezovskiy I., Ryschich E., Zoller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res 2006, 66:7083-7094.
54. Nazarenko I., Rana S., Baumann A., McAlear J., Hellwig A., Trendelenburg M., et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res 2010, 70:1668-1678.
55. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009, 16:196-208.
56. Jubb A.M., Turley H., Moeller H.C., Steers G., Han C., Li J.L., et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer 2009, 101:1749-1757.
57. Sheldon H., Heikamp E., Turley H., Dragovic R., Thomas P., Oon C.E., et al. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 2010, 116:2385-2394.
58. Al-Nedawi K., Meehan B., Kerbel R.S., Allison A.C., Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. PNAS 2009, 106:3794-3799.
59. Graner M.W., Alzate O., Dechkovskaia A.M., Keene J.D., Sampson J.H., Mitchell D.A., et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J 2009, 23:1541-1557.
60. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Curry W.T., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
61. Hong B.S., Cho J.-H., Kim H., Choi E.-J., Rho S., Kim J., et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009, 10.
62. Valadi H., Ekström K., Bossios A., Sjöstrand M., Lee J.J., Lötvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
63. Umezu T., Ohyashiki K., Kuroda M., Ohyashiki J.H. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013, 32:2747-2755.
64. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011, 71:5346-5356.
65. Vaupel P., Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metast Rev 2007, 26:225-239.
66. Wysoczynski M., Ratajczak M.Z. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 2009, 125:1595-1603.
67. Orriss I.R., Knight G.E., Utting J.C., Taylor S.E., Burnstock G., Arnett T.R. Hypoxia stimulates vesicular ATP release from rat osteoblasts. J Cell Physiol 2009, 220:155-162.
68. Wang T., Gilkes D.M., Takano N., Xiang L., Luo W., Bishop C.J., et al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA 2014, 111(31):E3234-E3242. 10.1073/pnas.1410041111.
69. King H., Michael M., Gleadle J. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12:421.
70. Tadokoro H., Umezu T., Ohyashiki K., Hirano T., Ohyashiki J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem 2013, 288:34343-34351.
71. Kucharzewska P., Christianson H.C., Welch J.E., Svensson K.J., Fredlund E., Ringnér M., et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 2013, 110:7312-7317.
72. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006, 6:392-401.
73. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., Rowley D.R. Reactive stroma in human prostate cancer. Clin Cancer Res 2002, 8:2912-2923.
74. Özdemir Berna C., Pentcheva-Hoang T., Carstens Julienne L., Zheng X., Wu C.-C., Simpson Tyler R., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25:719-734.
75. Rhim Andrew D., Oberstein Paul E., Thomas Dafydd H., Mirek Emily T., Palermo Carmine F., Sastra Stephen A., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25:735-747.
76. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 2010, 70:9621-9630.
77. Webber J.P., Spary L.K., Sanders A.J., Chowdhury R., Jiang W.G., Steadman R., et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene 2014, 34:290-302.
78. Ostrowski M., Carmo N.B., Krumeich S., Fanget I., Raposo G., Savina A., et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010, 12:19-30.
79. Polanska U.M., Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013, 228:1651-1657.
80. Cho J.A., Park H., Lim E.H., Lee K.W. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol 2012, 40:130-138.
81. Gu J., Qian H., Shen L., Zhang X., Zhu W., Huang L., et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS ONE 2012, 7:e52465.
82. Atay S., Banskota S., Crow J., Sethi G., Rink L., Godwin A.K. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc Natl Acad Sci USA 2014, 111:711-716.
83. Luga V., Zhang L., Viloria-Petit Alicia M., Ogunjimi Abiodun A., Inanlou Mohammad R., Chiu E., et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell 2012, 151:1542-1556.
84. Ekström E.J., Bergenfelz C., von Bülow V., Serifler F., Carlemalm E., Jönsson G., et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer 2014, 13:88.
85. Zhu W., Huang L., Li Y., Zhang X., Gu J., Yan Y., et al. Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett 2012, 315:28-37.
86. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.-T., Reagan M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013, 123:1542-1555.
87. Bruno S., Collino F., Deregibus M.C., Grange C., Tetta C., Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem cells Dev 2013, 22:758-771.
88. Hood J.L., San R.S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011, 71:3792-3801.
89. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012, 18:883-891.
90. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
91. Bobrie A., Krumeich S., Reyal F., Recchi C., Moita L.F., Seabra M.C., et al. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. Cancer Res 2012, 72:4920-4930.
92. Jung T., Castellana D., Klingbeil P., Hernández I.C., Vitacolonna M., Orlicky D.J., et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia (New York, NY) 2009, 11:1093-1117.
93. Gong J., Jaiswal R., Mathys J.M., Combes V., Grau G.E.R., Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 2012, 38:226-234.
94. Geddings J.E., Mackman N. Tumor-derived tissue factor - positive microparticles and venous thrombosis in cancer patients. Blood 2013, 122:1873-1880.
95. Marleau A., Chen C.-S., Joyce J., Tullis R. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012, 10:134.